Odiven

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Odiven

Odiven is a prescription-only medicine containing the active ingredient Venlafaxine, which is utilized for the management of psychiatric disorders. It belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class of drugs.


Quick Facts: Odiven Identity

Property Description
Active Ingredient Venlafaxine (as hydrochloride)
Primary Form Prolonged-release capsules
Pharmacological Class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Origin Synthetic compound
Route of Administration Oral administration

Type, Classification, and Composition

The foundation of Odiven is the single active ingredient Venlafaxine, a synthetic compound classified as a psychotropic agent. This classification confirms its action on the central nervous system. As an antidepressant, Venlafaxine is placed within the SNRI group, a classification clinically recognized for its dual reuptake inhibition mechanism. The medicine is primarily supplied for oral administration in prolonged-release capsules, which are a type of extended-release formulation. This specific pharmaceutical form helps ensure a gradual and consistent delivery of the active ingredient over time for adults requiring sustained therapeutic action.

General Mechanism and Purpose

The general purpose of Odiven is to help restore chemical balance in the brain. Functionally, it is a dual reuptake inhibitor that targets both the serotonin (5-HT) transporters and norepinephrine (NE) transporters. By enhancing the availability of both neurotransmitters, it facilitates improved communication in the brain. The medical consensus shows that this mechanism is effective in stabilizing mood and supporting psychological function. Odiven's targeted approach is used to achieve the general benefit of stabilizing and regulating mood states in patients.

Regulatory References

  1. MeSH Descriptor Data for Venlafaxine

What side effects are possible with Odiven?

Possible Side Effects and Safety Information

The safety profile for Odiven (Venlafaxine) is structured by regulatory authorities to classify potential adverse reactions based on clinical trial frequency and the organ system affected. Side effects are classified into tiers to communicate the documented likelihood of occurrence.

Frequency-Classified Adverse Reactions

The official labeling notes several categories of effects. Very Common reactions (ge 1/10) typically documented include headache, nausea, dry mouth, and sweating (including night sweats). Common reactions (ge 1/100 to < 1/10) involve reactions such as dizziness, insomnia, constipation, hypertension, palpitations, and anxiety.

System-Organ Class Groupings

Adverse effects are also grouped by the physiological system impacted. Noted systems include Gastrointestinal Disorders (e.g., vomiting, decreased appetite), Nervous System Disorders (e.g., tremor, somnolence), Psychiatric Disorders (e.g., abnormal dreams), Cardiovascular Disorders, and Reproductive System Disorders (e.g., sexual dysfunction).

Serious Adverse Reactions and Safety Constraints

The label identifies several serious adverse reactions. These include Serotonin Syndrome, sustained hypertension, angle-closure glaucoma, and an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults (age 18–24). The medicine is strictly contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs). Regulatory documents also require caution in patients with pre-existing conditions like seizure disorders or unstable heart disease.

Population and Exposure Considerations

Population-specific safety statements advise caution and potential adjustment for patients with hepatic or renal impairment due to reduced clearance. Side effects are often more frequent during the initial phase of treatment or following dose increases. Discontinuation symptoms may occur upon abrupt cessation, necessitating gradual dose reduction.

Overdose and Emergency Response

Overdose and When to Seek Help: Regulatory Guidance

Overdosage with Odiven (Venlafaxine) is officially documented as a serious event that can be severe and may result in fatal outcomes. Official guidance mandates that immediate medical attention must be sought, and emergency services must be contacted immediately if an overdose is suspected or if signs of severity develop.


Documented Manifestations and Severe Outcomes

The officially recognized clinical signs of overdose primarily affect the central nervous and cardiovascular systems. Documented central nervous system effects include somnolence, sedation, convulsions (seizures), and a decreased level of consciousness progressing to coma. Cardiovascular manifestations include tachycardia (rapid heart rate) and ECG changes, such as QRS prolongation.

The regulatory labeling specifically identifies Serotonin Syndrome (Serotonin Toxicity) as a potentially life-threatening complication of overdosage.


Official Management and Actions

Official prescribing information states that no specific antidote is known for Venlafaxine overdose. Therefore, treatment is strictly symptomatic and supportive. Supportive measures described in regulatory documents include continuous monitoring of cardiac rhythm and vital signs, alongside procedures such as gastric lavage and the administration of activated charcoal to limit drug absorption.

Therapeutic Uses of Odiven

What Odiven Treats: Main Uses and Benefits

Odiven (Venlafaxine) is a prescription medicine commonly used to provide supportive therapeutic benefits across several key domains marked by increased discomfort and symptomatic distress. The medication is relevant for managing conditions that present with episodic or fluctuating manifestations and where symptoms create noticeable interference with functional stability.

This medication is relevant for managing conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder. It is applied across domains where additional symptomatic support is needed, assisting patients during phases of increased distress or discomfort.

Odiven is applied in addressing symptom clusters that may become intense or disruptive, such as persistent sadness, loss of pleasure (anhedonia), chronic worry, tension, and recurrent panic attacks. Beyond mood and anxiety, it contributes to easing the symptom load in scenarios involving physical discomfort, such as hot flashes and certain chronic neuropathic pain syndromes. The therapeutic use helps maintain a sense of stability and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Key Symptom Domains
Mood: Helps manage persistent sadness and emotional instability.
Anxiety: Supports relief from uncontrollable worry and acute fear episodes.
Somatic: Applied to ease symptoms of hot flashes and neuropathic pain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules for Odiven (Venlafaxine)

Odiven is an SNRI medicine with specific eligibility criteria documented in regulatory labeling. The medicine is approved only for use in adults aged 18 years and older; safety and efficacy have not been established for use in pediatric patients.


Absolute Contraindications

Odiven must not be used by certain patient groups to prevent serious complications. This includes patients with a documented hypersensitivity to venlafaxine or any of its components, and patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI), or who have stopped an MAOI in the last 14 days. This prohibition also extends to patients using linezolid or intravenous methylene blue.


Conditional and Restricted Use

Use is conditional in populations where clearance of the medicine may be impaired. Patients with renal or hepatic impairment require a mandated dose reduction, as defined in prescribing information, due to the limited capacity of the liver or kidneys to process the drug. For pregnancy, use is advised only if clearly needed. For nursing mothers, the regulatory label recommends discontinuing the drug or discontinuing nursing due to the potential for adverse effects on the infant. Caution is also advised in patients with a history of bipolar disorder or untreated narrow-angle glaucoma.

What should I know about interactions with other medicines?

Odiven (Venlafaxine) interactions are formally documented by regulatory authorities, classifying combinations based on pharmacokinetic (PK) and pharmacodynamic (PD) risks.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders is strictly prohibited. This restriction also applies to other substances with MAOI activity, such as Linezolid and Intravenous Methylene Blue. Due to the risk of Serotonin Syndrome, a washout period is required when switching between these agents: at least 14 days after stopping an MAOI before starting Odiven, and at least 7 days after stopping Odiven before starting an MAOI.

Documented Interaction Patterns

Pharmacodynamic Interactions

Co-administration with other serotonergic agents (e.g., Triptans, Tramadol, SSRIs) may lead to additive effects, increasing the risk of Serotonin Syndrome. Additionally, combining Odiven with drugs that interfere with hemostasis (such as NSAIDs or Aspirin) increases the risk of abnormal bleeding events, a PD interaction noted in official labeling.

Pharmacokinetic and Substance Interactions

  • CYP Enzyme Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole) increases the plasma exposure (AUC and Cmax) of both Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV).
  • Alcohol: The ingestion of alcohol is documented to increase the release rate of the Odiven prolonged-release capsule formulation.
  • Food: Food does not affect the overall bioavailability (extent of absorption) of the active compounds.

Mechanism of Action

Odiven (Venlafaxine) acts via the dual inhibition of neurotransmitter reuptake within the central nervous system. Its mechanism involves competitive blockade of two primary molecular targets: the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). The parent drug and its active metabolite, O-desmethylvenlafaxine, prevent the rapid clearance of serotonin and norepinephrine from the synaptic cleft, resulting in their prolonged presence and enhanced availability in neural circuits.

This dual action is concentration-dependent; Odiven exhibits a higher affinity for SERT than for NET. Consequently, pathway engagement is predominantly serotonergic at lower concentrations, transitioning to affect noradrenergic pathways secondarily as the concentration increases. The sustained enhancement of monoamine signaling also initiates long-term adaptive physiological responses, including the upregulation of Brain-Derived Neurotrophic Factors (BDNFs). These changes lead to adaptive alterations in the neuronal circuitry, influencing the structural and functional capacity within targeted pathways.

Dosage and Administration Information

Odiven is administered orally and is prescribed as a prolonged-release capsule. The medicine is taken once daily at approximately the same time each day, a schedule mandated to ensure consistent delivery of the active ingredient. Official instructions require the medicine to be taken with food.

Official Dosing Patterns

The standard adult starting dose for many uses, such as Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD), is typically 75 mg once daily, though some regimens may start lower at 37.5 mg for an initial period. The maintenance dose ranges from 75 mg up to 225 mg once daily, with 225 mg being the maximum recommended daily dose for most indications. Dosage adjustments, when necessary, are made incrementally at intervals of no less than four to seven days.

Administration and Handling

To preserve the prolonged-release mechanism, the capsule must be swallowed whole with fluid and must not be divided, chewed, crushed, or dissolved. As an alternative, the official label permits opening the capsule and sprinkling its contents onto a small amount of applesauce for immediate swallowing, without chewing. Specific dose reductions are required for patients with compromised renal or hepatic function, often involving a 25% to 50% reduction in the total daily dose.

Concluding Treatment

Treatment must not be stopped abruptly. The usage protocol requires a gradual dose reduction (tapering) process when concluding the course of use, commonly involving a dose reduction of 75 mg at one-week intervals or more gradually as determined by the patient's overall regimen.

Recent Clinical Evidence

Research Evidence Overview of Studies for Odiven

The information below summarizes the clinical research and evidence base for Odiven (Venlafaxine), focusing on the types of studies conducted, the outcomes they examined, and what remains uncertain, based on official regulatory and scientific sources. This is a descriptive overview, not clinical advice.


## Evidence Supporting Use in Major Depressive Disorder (MDD)

Research has explored Odiven in conditions characterized by fluctuating or episodic manifestations, such as Major Depressive Disorder (MDD), through short-term, placebo-controlled clinical trials. These studies were used in research exploring how symptoms change over time in adult outpatients with MDD. Researchers primarily monitored outcomes related to symptom intensity or variability using standardized tools. Findings describe patterns observed in the studies where groups assigned to Odiven had changes in their depression symptom scores that were distinct from those assigned to placebo during the short observation period. Additional studies report how symptoms evolved in the observed populations in the long-term follow-up, where recurrence rates were tracked over the monitored duration.

## Studies for Anxiety Disorders (GAD and SAD)

For Generalized Anxiety Disorder (GAD), studies conducted during periods of increased symptom activity researched conditions involving periods of heightened symptoms. The research explored how symptoms changed over defined time intervals, usually through short-term placebo-controlled trials, monitoring outcomes reflecting daily functioning and anxiety severity. Research explored Odiven in studies for Social Anxiety Disorder (SAD), where short-term trials measured outcomes describing episodic changes using tools like the LSAS scale.

## What is Still Uncertain About Odiven's Evidence Base

A key limitation is that many primary trials excluded patients with other significant medical or psychiatric comorbidities, meaning the results apply most directly only to the populations studied. Data for certain groups, such as those with complex anxiety profiles or pediatric populations, remain insufficient for all outcomes. Comparative evidence is lacking in certain scenarios, and evidence quality varies across studies. Ultimately, the research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Odiven (FAQ)


Q: Is it common to feel worse before feeling better when starting Odiven?

Official information emphasizes that all antidepressant-treated patients are to be closely observed for any clinical worsening, and the emergence of suicidal thoughts and behaviors, especially during the initial months of therapy or when the dosage is changed. Regulatory texts note that depression itself is a risk factor for symptoms that require close monitoring as treatment progresses.


Q: Does Odiven have a generic equivalent available?

Yes. The active ingredient in Odiven is Venlafaxine. According to authoritative medical sources, this compound is available under its non-proprietary name in various forms, including as a generic extended-release capsule or tablet.


Q: Can taking Odiven affect blood pressure readings?

Official product information states that treatment with Odiven has been associated with sustained increases in blood pressure (hypertension). For this reason, regulatory guidance indicates that blood pressure be assessed before starting treatment and monitored regularly throughout the course of therapy.


Q: Can Odiven cause dry mouth, and are there general care suggestions for this?

Dry mouth is listed as a very common side effect in official documents. For managing this discomfort, patient guidance from authoritative sources sometimes lists using sugarless candy or gum as a measure to stimulate saliva flow.


Q: What is the general description of the duration of Odiven's effects after a single administration?

Odiven is an extended-release medicine specifically formulated for once-daily use. The drug's design allows for the active compounds to be released gradually over a 24-hour period, which supports its sustained therapeutic effect within a standard dosing interval.


Q: How is Odiven different from SSRI drugs?

Odiven is classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Its mechanism involves blocking the reuptake of two key chemical messengers in the brain—serotonin and norepinephrine. In contrast, medicines in the SSRI class primarily affect only serotonin reuptake.


Q: What is the typical timeframe for people to notice the effects of Odiven?

While the active compounds in the drug reach consistent levels in the body within a few days, the full therapeutic benefit is typically assessed over an extended period. Studies used to establish effectiveness generally involve observation periods of 8 to 12 weeks to evaluate the full change in symptoms.


Q: Is it necessary to avoid certain foods or drinks while on Odiven?

Official instructions specify that Odiven should be taken with food. While there are no general restrictions on standard foods, regulatory guidance indicates that the concurrent use of alcohol is generally not recommended.


Q: Does Odiven have known interactions with grapefruit or grapefruit juice?

Odiven is processed by the CYP3A4 enzyme system in the body. Although a strict restriction is not universally applied, some regulatory guidance advises caution with substances, including grapefruit, that may potentially increase the amount of Odiven in the bloodstream.


Q: What is the information regarding the use of Odiven and alcohol?

Official regulatory guidance indicates that patients should not consume alcohol while on Odiven. Regulatory texts note that alcohol may increase the rate at which the drug is released from the capsule and can also increase the risk of central nervous system side effects.


Q: Is there a known effect of Odiven on weight, either gain or loss?

Official documentation reports that anorexia (decreased appetite) and subsequent weight loss have been observed as adverse reactions in clinical trials involving patients treated with the active ingredient in Odiven.


Q: Can Odiven affect sexual function, and is this effect usually temporary?

Sexual dysfunction is a documented common side effect of the drug. Patient-facing information notes that such effects may potentially diminish as the body adjusts, but the duration of this side effect can vary among individuals and may persist throughout treatment for some.


Q: What are the general guidelines for use of Odiven in elderly patients?

Data indicates that dosage selection for elderly patients is typically approached cautiously, often beginning at the lower end of the dosing range. This is due to the greater likelihood of reduced function in organs like the liver or kidneys, and the potential presence of other health conditions or medications.


Q: What is the guidance on driving or operating machinery while taking Odiven?

Odiven is associated with adverse reactions like dizziness and somnolence (drowsiness). Regulatory caution advises patients to be mindful when performing tasks requiring full alertness, such as driving or operating heavy machinery, due to the potential for impaired judgment and motor skills.


Q: Is Odiven described as habit-forming or addictive?

The official regulatory label does not classify the active ingredient in Odiven as a controlled substance and does not describe it using the term 'addictive.' However, the process of gradual dose reduction (tapering) is required to minimize discontinuation symptoms when stopping the medicine.


Q: What is the information about Odiven and potential effects on blood sugar levels?

Regulatory guidance notes that Odiven may make it more challenging to maintain stable blood sugar levels. For patients with diabetes, closer monitoring of blood sugar may be indicated during the initial weeks of treatment.


Q: What is the guidance on what to do if an allergic reaction is suspected?

Authoritative patient guides recommend seeking immediate medical assistance if signs of a severe allergic reaction—such as trouble breathing, swelling of the face, tongue, or throat, or a severe skin reaction—are observed.


Q: Is it possible for Odiven to affect menstrual cycles?

Official documentation lists menorrhagia (heavy menstrual bleeding) and other 'menstrual disorders' as documented adverse reactions related to the reproductive system, indicating a potential effect on the menstrual cycle.


Q: What are the known potential effects of Odiven on dental health or teeth?

The drug is known to cause dry mouth as a very common side effect. Although the label does not explicitly list dental decay, official warnings indirectly suggest that persistent dry mouth can increase the risk of subsequent dental health issues.


Q: Is there a non-directive description of who is generally eligible to use Odiven?

Odiven is approved for use in adults to help manage certain psychiatric conditions. According to official indications, these conditions include Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Social Anxiety Disorder (SAD).

How should Odiven be stored and disposed of?

Storage and Disposal of Odiven (Venlafaxine Hydrochloride)

Odiven must be stored under specific conditions to maintain the stability of the venlafaxine active ingredient. The required storage temperature is 20ºC to 25ºC (68ºF to 77ºF), which is defined as controlled room temperature. The product must be protected from destabilizing environmental factors, meaning it should be stored in a tight, light-resistant container and kept away from excessive heat and moisture.

All medicines must be kept out of the sight and reach of children and pets to prevent accidental ingestion.

For disposal, unused or expired Odiven must be handled according to federal, state, and local regulations. The preferred method is to utilize community drug take-back programs. The medicine should not be flushed to sewer or released into surface waters, as stipulated in environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Odiven found in:

A-Z Index: